387 related articles for article (PubMed ID: 25251387)
1. Targeting extra-gonadal androgens in castration-resistant prostate cancer.
Grist E; de Bono JS; Attard G
J Steroid Biochem Mol Biol; 2015 Jan; 145():157-63. PubMed ID: 25251387
[TBL] [Abstract][Full Text] [Related]
2. Improved therapeutic targeting of the androgen receptor: rational drug design improves survival in castration-resistant prostate cancer.
Lim AC; Attard G
Curr Drug Targets; 2013 Apr; 14(4):408-19. PubMed ID: 23565754
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of drug resistance that target the androgen axis in castration resistant prostate cancer (CRPC).
Penning TM
J Steroid Biochem Mol Biol; 2015 Sep; 153():105-13. PubMed ID: 26032458
[TBL] [Abstract][Full Text] [Related]
4. Targeting persistent androgen receptor signaling in castration-resistant prostate cancer.
Graham L; Schweizer MT
Med Oncol; 2016 May; 33(5):44. PubMed ID: 27042852
[TBL] [Abstract][Full Text] [Related]
5. Androgen pathway resistance in prostate cancer and therapeutic implications.
Maughan BL; Antonarakis ES
Expert Opin Pharmacother; 2015; 16(10):1521-37. PubMed ID: 26067250
[TBL] [Abstract][Full Text] [Related]
6. Combined blockade of testicular and locally made androgens in prostate cancer: a highly significant medical progress based upon intracrinology.
Labrie F
J Steroid Biochem Mol Biol; 2015 Jan; 145():144-56. PubMed ID: 24925260
[TBL] [Abstract][Full Text] [Related]
7. Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor.
Coleman DJ; Van Hook K; King CJ; Schwartzman J; Lisac R; Urrutia J; Sehrawat A; Woodward J; Wang NJ; Gulati R; Thomas GV; Beer TM; Gleave M; Korkola JE; Gao L; Heiser LM; Alumkal JJ
Oncotarget; 2016 Jun; 7(26):40690-40703. PubMed ID: 27276681
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer.
Xiao L; Tien JC; Vo J; Tan M; Parolia A; Zhang Y; Wang L; Qiao Y; Shukla S; Wang X; Zheng H; Su F; Jing X; Luo E; Delekta A; Juckette KM; Xu A; Cao X; Alva AS; Kim Y; MacLeod AR; Chinnaiyan AM
Cancer Res; 2018 Oct; 78(20):5731-5740. PubMed ID: 30135193
[TBL] [Abstract][Full Text] [Related]
9. Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling.
Moll JM; Hofland J; Teubel WJ; de Ridder CMA; Taylor AE; Graeser R; Arlt W; Jenster GW; van Weerden WM
Prostate; 2022 Apr; 82(5):505-516. PubMed ID: 35037287
[TBL] [Abstract][Full Text] [Related]
10. Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone.
Bianchini D; Lorente D; Rodriguez-Vida A; Omlin A; Pezaro C; Ferraldeschi R; Zivi A; Attard G; Chowdhury S; de Bono JS
Eur J Cancer; 2014 Jan; 50(1):78-84. PubMed ID: 24074764
[TBL] [Abstract][Full Text] [Related]
11. Androgen receptor aberrations in the era of abiraterone and enzalutamide.
Jentzmik F; Azoitei A; Zengerling F; Damjanoski I; Cronauer MV
World J Urol; 2016 Mar; 34(3):297-303. PubMed ID: 26100946
[TBL] [Abstract][Full Text] [Related]
12. Persistent androgen receptor addiction in castration-resistant prostate cancer.
Schweizer MT; Yu EY
J Hematol Oncol; 2015 Nov; 8():128. PubMed ID: 26566796
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis.
Yuan X; Cai C; Chen S; Chen S; Yu Z; Balk SP
Oncogene; 2014 May; 33(22):2815-25. PubMed ID: 23752196
[TBL] [Abstract][Full Text] [Related]
14. Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer.
Buttigliero C; Tucci M; Bertaglia V; Vignani F; Bironzo P; Di Maio M; Scagliotti GV
Cancer Treat Rev; 2015 Dec; 41(10):884-92. PubMed ID: 26342718
[TBL] [Abstract][Full Text] [Related]
15. Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.
Richards J; Lim AC; Hay CW; Taylor AE; Wingate A; Nowakowska K; Pezaro C; Carreira S; Goodall J; Arlt W; McEwan IJ; de Bono JS; Attard G
Cancer Res; 2012 May; 72(9):2176-82. PubMed ID: 22411952
[TBL] [Abstract][Full Text] [Related]
16. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
Karantanos T; Evans CP; Tombal B; Thompson TC; Montironi R; Isaacs WB
Eur Urol; 2015 Mar; 67(3):470-9. PubMed ID: 25306226
[TBL] [Abstract][Full Text] [Related]
17. Androgen receptor splice variants in the era of enzalutamide and abiraterone.
Nakazawa M; Antonarakis ES; Luo J
Horm Cancer; 2014 Oct; 5(5):265-73. PubMed ID: 25048254
[TBL] [Abstract][Full Text] [Related]
18. Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.
Welti J; Rodrigues DN; Sharp A; Sun S; Lorente D; Riisnaes R; Figueiredo I; Zafeiriou Z; Rescigno P; de Bono JS; Plymate SR
Eur Urol; 2016 Oct; 70(4):599-608. PubMed ID: 27117751
[TBL] [Abstract][Full Text] [Related]
19. Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting.
Luo J; Attard G; Balk SP; Bevan C; Burnstein K; Cato L; Cherkasov A; De Bono JS; Dong Y; Gao AC; Gleave M; Heemers H; Kanayama M; Kittler R; Lang JM; Lee RJ; Logothetis CJ; Matusik R; Plymate S; Sawyers CL; Selth LA; Soule H; Tilley W; Weigel NL; Zoubeidi A; Dehm SM; Raj GV
Eur Urol; 2018 May; 73(5):715-723. PubMed ID: 29258679
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
